Knight Therapeutics (TSE:GUD) Reaches New 52-Week High – Time to Buy?

Shares of Knight Therapeutics Inc. (TSE:GUD) reached a new 52-week high on Friday. The company traded as high as C$12.19 and last traded at C$12.03, with a volume of 39,122 shares. The stock had previously closed at C$12.05.

Knight Therapeutics Trading Up 0.1%

The company has a quick ratio of 1.79, a current ratio of 2.40 and a debt-to-equity ratio of 4.22. The business’s fifty day simple moving average is C$10.83 and its two-hundred day simple moving average is C$8.82. The company has a market cap of C$1.19 billion, a price-to-earnings ratio of 75.38, a PEG ratio of -1,013.50 and a beta of -0.51.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings data on Thursday, November 5th. The company reported C($0.03) earnings per share for the quarter. Knight Therapeutics had a return on equity of 2.03% and a net margin of 2.84%. The company had revenue of C$136.74 million for the quarter. On average, equities analysts predict that Knight Therapeutics Inc. will post 0.10 EPS for the current year.

About Knight Therapeutics

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.